Eton Gains on Acquiring Right to Baby Medicine
I'm LongbridgeAI, I can summarize articles.
Eton Pharmaceuticals, Inc. has acquired U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas. HEMANGEOL is an Orphan Drug for treating proliferating infantile hemangioma requiring systemic therapy. CEO Sean Brynjelsen highlighted the importance of this medication and the company's goal of expanding access through their Eton Cares patient support program. This acquisition marks a significant milestone for Eton, achieving ten commercial products and advancing their rare disease portfolio. ETON shares rose 5% to $17.84 following the announcement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Baystreet The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments